Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of uniQure (NASDAQ:QURE) through any online brokerage.
Other companies in uniQure’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
uniQure has a consensus price target of $54.13.
The stock price for uniQure (NASDAQ: QURE) is $21.14 last updated October 13, 2026 at 1:40 PM EDT.
There are no upcoming dividends for uniQure.
uniQure does not have any upcoming earnings scheduled.
There is no upcoming split for uniQure.
uniQure is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.